With the S&P 500 falling at this rate, the stock market could be at risk of triggering a circuit breaker.

9 Nintendo Switch 2 Games It NEEDS to Have - Super Mario Odyssey 2 & More! Watch on YouTube The second phase of Nintendo's game launch plan is then reportedly set for around October-November ...

GameSpot may get a commission from retail offers. The Nintendo Switch 2 is reportedly launching in June, with a three-phase plan for rolling out both first- and third-party games throughout the ...

The Switch 2 will launch in June, and Nintendo will carry out the Switch 2's initial game release structure in a three-phase plan, sources tell Insider Gaming. Some of Nintendo's strategies for ...

Findings showed statistically significant reductions in the ADHD Investigator Symptom Report Scale total score were seen with solriamfetol 150mg vs placebo at week 6. Topline data were announced ...

Editor’s note: This is a developing news story. Please check back soon for updates. The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Shortly after paying $800 million to take full control of BNT327, the biotech began a phase 3 trial to test the bispecific in combination with chemo in patients with previously untreated extensive ...

REFOCUS-ALZ enrolled 1,125 patients and was discontinued on November 25, 2024, following the report that a prior 52-week Phase 3 study, RETHINK-ALZ, did not meet its co-primary endpoints.

Cassava Sciences (SAVA) shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD. Topline data indicate that REFOCUS-ALZ did not meet each of the prespecified ...

Cassava Sciences' simufilam failed to meet co-primary endpoints in the Phase 3 REFOCUS-ALZ trial for mild-to-moderate Alzheimer's disease. Cassava will discontinue Alzheimer's drug development ...